[ad_1]
– Neritorimod, a class C TLR-9 agonist formerly known as SD-101, is the company’s therapeutic candidate designed to overcome biological barriers in liver and pancreatic tumors.
– Neritorimod is currently being evaluated in three Phase 1/1b studies in adults with liver and pancreatic cancer in combination with TriSalus’ proprietary Pressure Enabled Drug Delivery™ technology.
Denver, March 7, 2024–(BUSINESS WIRE)–TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technologies and immunotherapies to transform the treatment of patients with liver and pancreatic tumors, today announced that The National Names (INN) Expert Panel and the United States Adopted Names (USAN) Council have approved the use of the common name “”.NeritorimodNeritorimod is a new drug candidate for SD-101, a class C TLR-9 agonist, for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma.
“The approval of neritorimod by WHO INN and USAN is an important milestone in the continued advancement of our neritorimod program,” said Mary Shera, Chief Executive Officer and President of TriSalus. “This achievement, and the recent assignment of a new technology HCPCS code to our TriNav,® The infusion system will enable TriSalus to overcome key treatment barriers for liver and pancreatic tumors and fulfill our mission to make a meaningful difference in the lives of patients suffering from cancer. ”
TriSalus’ unique approach leverages innovative delivery devices and immunotherapeutic agents to overcome mechanical and biological barriers present in the tumor microenvironment. This approach may enable more durable patient responses to other immunotherapies, thereby promoting improved patient outcomes. TriSalus’ Phase 1/1b trial data show that the company’s approach for liver and pancreatic tumors promotes efficacy and immune signals and is well-tolerated, showing that neritolimod is delivered by the TriNav system There is evidence that it can be delivered to difficult tumors and potentially overcome the limitations of adverse effects. Intravenous or direct needle injection approach.
Information about nelitolimod is posted on the USAN website (www.ama-assn.org/go/usan) and is also published in the Chemical Abstracts Service and the United States Pharmacopeia. WHO provides her INN to WHO Member States (currently 191 countries), national pharmacopoeia committees, and other bodies designated by WHO Member States.
The name nelitolimod is now available for use in labeling and publications. This will help identify during the lifetime of his SD-101 around the world. Going forward, TriSalus will use its name in publications, public statements, conferences and other forums, and corporate materials.
About TriSalus Life Sciences
TriSalus Life Sciences is an oncology company that integrates novel delivery technologies and immunotherapies to transform the treatment of patients with liver and pancreatic tumors.
The company’s platform includes devices that utilize proprietary drug delivery technologies and clinical-stage investigational immunotherapies. The company’s two FDA-cleared devices use a proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a variety of therapeutic agents.® Hepatic artery infusion system for liver tumors and pancreatic retrograde intravenous infusion system for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomical limitations of arterial injection into the pancreas. The PEDD approach is designed to modulate pressure and flow in a way that delivers more therapeutic agent to the tumor and reduces unwanted delivery to normal tissue, offering the potential to improve patient outcomes. The company’s investigational immunotherapy candidate, SD-101, improves patient outcomes by treating the immunosuppressive environment created by many tumors where current immunotherapies can be ineffective in the liver and pancreas. is designed to. Patient data generated during the Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trial support the hypothesis that SD-101 delivered via PEDD may have favorable intrahepatic and systemic immune effects. I am. TLR9, the target of SD-101, is expressed in a variety of cancer types, and mechanical barriers that are addressed by PEDD are also commonly present. SD-101, delivered by PEDD, will be studied across several indications to address immune dysfunction and overcome liver and pancreatic drug delivery barriers.
TriSalus partners with leading cancer centers across the country, leveraging its deep expertise in immuno-oncology and unique technology development to drive innovation that improves patient outcomes. Learn more and follow us at trisaluslifesci.com. X (old Twitter) And LinkedIn.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240307072002/ja/
contact address
Investor inquiries:
james young
Senior Vice President, Investor Relations/Finance
847.337.0655
james.young@trisaluslifesci.com
Media inquiries:
Stephanie Jacobson
Argot Partners
610.420.3049
TriSalus@argotpartners.com
[ad_2]
Source link
